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Chronic congestive heart failure (CHF) is a syndrome in which cardiac dysfunction is associated with high morbidity and mortality. Severe symptomatic heart failure is the end point of a lengthy sequence of events, in which the functional state of the left ventricle is an important determinant of the prognosis. As well as the severity of the symptoms of heart failure and the depression of left ventricular ejection fraction, which are independent predictors of survival in heart failure, the neuroendocrine activation found in these patients is directly related to the outcome. It has been shown in controlled trials that one of the most important therapeutic aims to improve survival in patients with chronic CHF must be the inhibition of vasoconstrictor and sodium and water retaining neurohumoral factors. 2 The table summarises neuroendocrine mechanisms that may be activated in heart failure.
Stimulation of the renin angiotensin-aldosterone system in patients with severe CHF was first described in the 1940s.34 There is convincing experimental and clinical evidence that neuroendocrine systems are already activated in the very early stages of heart failure and that they interact in different ways in different phases of the disease.56 Even when plasma renin activity is within the normal range in early heart failure, there is experimental evidence for at least The renin-angiotensin system is activated in nearly all patients early after infarction and rises progressively over the first three days not only in patients with overt heart failure but also in patients with no clinical complications. Increased concentrations of catecholamines, renin, and angiotensin II up to 10 days after admission to hospital were associated with extensive myocardial infarction, low left ventricular ejection fraction, heart failure, ventricular tachycardia, and death. In uncomplicated cases, when diuretics are not used, plasma renin activity gradually returns to normal, so that patients with asymptomatic left ventricular dysfunction have normal plasma renin concentrations at discharge from hospital. 9 14 In the survival and ventricular enlargement trial (SAVE) more than 500 patients had plasma neurohumoral concentrations measured at a mean of 12 days after infarction." 15 All patients had left ventricular dysfunction (ejection fraction <40%) without overt heart failure. In these patients, all neurohumoral concentrations (plasma renin activity, noradrenaline (norepinephrine), arginine vasopressin, atrial natriuretic peptide) were increased compared with age matched controls. These data show that in a subgroup of patients with significantly reduced left ventricular function at the time of discharge from hospital after an infarction, a persistent neurohumoral activation can be found.
The data contrast with results of the studies of left ventricular dysfunction (SOLVD) prevention group where asymptomatic patients with left ventricular dysfunction (ejection fraction <35%) were studied.'6 Eighty per cent of the patients had had a myocardial infarction >30 days previously (mean 3-5 years). In this trial patients had similar plasma noradrenaline concentrations as in the SAVE trial, but had lower plasma renin activity and plasma concentrations of arginine vasoNeuroendocrine mechanisms activated in heartfailure In patients with severe heart failure (New York Heart Association (NYHA) functional class IV), as was found in the cooperative north Scandinavian enalapril survival study (CONSENSUS), neuroendocrine mechanisms can be excessively active, showing a close association with survival.227 Cohn and co-workers investigated the neurohumoral state in more than 600 patients with mild and moderate heart failure (NYHA, functional classes II and III) who participated in the second Veterans Administration cooperative vasodilator-heart failure trial (V-HeFT II)28 and found heterogeneous neurohumoral stimulation without close correlation with clinical variables.29
